Clinical Trials Logo

Clinical Trial Summary

This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04139798
Study type Interventional
Source Bausch & Lomb Incorporated
Contact
Status Completed
Phase Phase 3
Start date July 20, 2020
Completion date March 12, 2021

See also
  Status Clinical Trial Phase
Completed NCT04140227 - Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study) Phase 3
Completed NCT04393441 - Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease Phase 3
Completed NCT04036292 - Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease Phase 3
Completed NCT04523142 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 Phase 3
Completed NCT03333057 - Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2
Completed NCT01998802 - Phase 3 Study of EBI-005 in Dry Eye Disease Phase 3
Completed NCT05723770 - Effects of NOV03 on the Tear Film Phase 4